Open main menu

Psychiatrienet β

Lurasidone-Fluphenazine LA

Revision as of 09:20, 16 March 2015 by Walter (talk | contribs) (Created page with '{{Drugswitch | from = Lurasidone | to = Fluphenazine_LA | stop = {{Downslweeks}} | start = {{StartDepot}} | info = {{caveQT}}{{Alternatief}} | view = Stop10WeeksStartDepot.jpg')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

{{Drugswitch | from = Lurasidone | to = Fluphenazine_LA | stop =

  • Week 1-3: approx. 75% of initial dose
  • Week 4-6: approx. 50% of initial dose
  • Week 7-9: approx. 25% of initial dose
  • Week 10: stop

| start =

  • Day 1: Start depot according general dosing advice (Dotted line in graph)

| info =

  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[1]
  • Alternatively, first switch to oral form and then switch to depot to manage possible (adverse) reactions. With a direct switch to a depot it is advisable to administer a low testdose in order to exclude adverse reactions.

| view = Stop10WeeksStartDepot.jpg

  1. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.